Application of machine learning in personalized medicine

Abstract

With the deepening of machine learning research in the medical field. At present, more and more studies have applied it to individualized medicine such as drug concentration monitoring and adverse reaction prediction. Compared with traditional population pharmacokinetic modeling methods, machine learning can analyze a large number of real-world medication data. Through multi-level mining of the data, machine learning can more accurately predict blood drug concentration and drug dose, so as to build a more practical individualized medication model, improve the level of clinical precision medication, and reduce the occurrence of adverse reactions. This article reviews the research of machine learning in individualized medicine, in order to provide technical support and theoretical basis for clinical precision medicine.

Keywords

Machine learning / Drug concentration monitoring / Adverse reaction prediction / Individualized medication

References

[1] Zhu Ronghuo, Huang Jingjing, Huang Hongna, et al. A model for predicting recurrence of hepatocellular carcinoma after hepatectomy based on four machine learning algorithms. J Integrated Chin Western Med Hepatol. 2023; 33 (3): 202- 208.

[2] Dercle L, Zhao B, Gönen M, et al. Early readout on overall survival of patients with melanoma treated with immunotherapy using a novel imaging analysis. PMID: 35050320; PMCID: PMC8778619 JAMA Oncol. 2022 Mar 1;8(3):385–392. https://doi.org/10.1001/jamaoncol.2021.6818.

[3] Zhai Xiaohui, Liu Xiaoxue, Lu Jiaqian, An Huimin, Zhou Peijun, Chen Bing. Simultaneous determination of several immunosuppressive agents in blood by LCMS/MS. Chin J Hosp Pharm. 2019; 39 (8): 774- 780.

[4] Zhang Jingyue, Feng Zhi, zhang jia-cheng, Hengjie Yuan, Liangfu Lv. Based on the improved curve regression model of the whole blood concentration of spore, A valley, central prediction. Chin J Hosp Pharm. 2021; 9 (15): 1491- 1495. + 1506.

[5] Yu Junxian, Xia Jie, Shi Limin, et al. Prediction model of cyclosporine A plasma concentration based on artificial neural network. Chinese Drug Appl Monit. 2010; 7 (1): 52- 55.

[6] Song L, Huang CR, Pan SZ, et al. A model based on machine learning for the prediction of cyclosporin A trough concentration in Chinese allo-HSCT patients. Epub 2022 Nov 16. PMID: 36373407 Expet Rev Clin Pharmacol. 2023 Jan;16(1):83–91. https://doi.org/10.1080/17512433.2023.2142561.

[7] Mao J, Chen Y, Xu L, et al. Applying machine learning to the pharmacokinetic modeling of cyclosporine in adult renal transplant recipients: a multi-method comparison. PMID: 36386138; PMCID: PMC9664902 Front Pharmacol. 2022 Oct 24; 13, 1016399. https://doi.org/10.3389/fphar.2022.1016399.

[8] Shao K, Jia Y, Lu J, et al. Estimation of mycophenolic acid exposure in Chinese renal transplant patients by a joint deep learning model. Ther Drug Monit. 2022 Dec 1; 44(6):738–746. https://doi.org/10.1097/FTD.0000000000001020. PMID: 36070781.

[9] Woillard JB, Labriffe M, Debord J, Marquet P. Mycophenolic acid exposure prediction using machine learning. Clin Pharmacol Ther. 2021 Aug;110(2):370–379. https://doi.org/10.1002/cpt.2216. Epub 2021 Apr 6. PMID: 33624286.

[10] Fu Xiaohua, Ye Yifang, Luo Meijuan, et al. Prediction of tacrolimus concentration in liver transplantation recipients by artificial neural network. Chinese J Pharm. 2012; 47 (9): 1134- 1140.

[11] Zheng P, Yu Z, Li L, et al. Predicting blood concentration of tacrolimus in patients with autoimmune diseases using machine learning techniques based on real-world evidence. PMID: 34630104; PMCID: PMC8497784 Front Pharmacol. 2021 Sep 24;12, 727245. https://doi.org/10.3389/fphar.2021.727245.

[12] Yuan W, Sui L, Xin H, Liu M, Shi H. Discussion on machine learning technology to predict tacrolimus blood concentration in patients with nephrotic syndrome and membranous nephropathy in real-world settings. PMID: 36539772; PMCID: PMC9764593 BMC Med Inf Decis Making. 2022 Dec 20;22(1):336. https://doi.org/10.1186/s12911-022-02089-w.

[13] Zhao Ting, Li Hongjian, Zhang Lihua, et al. Prediction of levetiracetam serum concentration in Uygur epilepsy children based on artificial neural network model. Chinese Modern Appl Pharm. 2021; 38 (22): 2875- 2880.

[14] Zhang Chen, Ni Suiqin, Wen Xianguan, et al. Application of GA-BP artificial neural network to predict the plasma concentration of sodium valproate. Today Pharm. 2014; 24 (1): 7- 10.

[15] Pan Ma, Jia Yuntao, Liu Fang, et al. Prediction of serum concentration of sodium valproate based on support vector machine. Anhui Med. 2021; 25 (1): 35- 39.

[16] Zhu X, Huang W, Lu H, et al. A machine learning approach to personalized dose adjustment of lamotrigine using noninvasive clinical parameters. PMID: 33692435; PMCID: PMC7946912 Sci Rep. 2021 Mar 10;11(1):5568. https://doi.org/10.1038/s41598-021-85157-x.

[17] Liu Zhaohui, Mei Quanxi, Huang Rongbo, et al. Prediction of risperidone steady-state plasma concentration by radial basis neural network. China Pharm. 2012; 23 (26): 2422- 2424.

[18] Guo W, Yu Z, Gao Y, et al. A machine learning model to predict risperidone active moiety concentration based on initial therapeutic drug monitoring. PMID: 34867511; PMCID: PMC8637165 Front Psychiatr. 2021 Nov 18;12, 711868. https://doi.org/10.3389/fpsyt.2021.711868.

[19] Zhu X, Hu J, Xiao T, Huang S, Wen Y, Shang D. An interpretable stacking ensemble learning framework based on multi-dimensional data for real-time prediction of drug concentration: the example of olanzapine. PMID: 36238557; PMCID: PMC9552071 Front Pharmacol. 2022 Sep 27;13, 975855. https://doi.org/10.3389/fphar.2022.975855.

[20] Zhang J, Wang Y, Zhang W, et al. The development and validation of a prediction model of lithium carbonate blood concentration by artificial neural network: a retrospective study. PMID: 36635997 Ann Palliat Med. 2022 Dec;11(12):3718–3726. https://doi.org/10.21037/apm-22-1237.

[21] Ma P, Liu R, Gu W, et al. Construction and interpretation of prediction model of teicoplanin trough concentration via machine learning. PMID: 35360734; PMCID: PMC8963816 Front Med. 2022 Mar 8;9, 808969. https://doi.org/10.3389/fmed.2022.808969.

[22] Bououda M, Uster DW, Sidorov E, et al. A machine learning approach to predict interdose vancomycin exposure. Epub 2022 Apr 11. PMID: 35411504 Pharm Res (N Y). 2022 Apr;39(4):721–731. https://doi.org/10.1007/s11095-022-03252-8.

[23] Huang X, Yu Z, Bu S, et al. An ensemble model for prediction of vancomycin trough concentrations in pediatric patients. PMID: 33883878; PMCID: PMC8053786 Drug Des Dev Ther. 2021 Apr 14;15:1549–1559. https://doi.org/10.2147/DDDT.S299037.

[24] Verhaeghe J, Dhaese SAM, De Corte T, et al. Development and evaluation of uncertainty quantifying machine learning models to predict piperacillin plasma concentrations in critically ill patients. BMC Med Inf Decis Making. 2022 Aug 25; 22(1):224. https://doi.org/10.1186/s12911-022-01970-y. PMID: 36008808; PMCID: PMC9404625.

[25] Modongo C, Pasipanodya JG, Zetola NM, Williams SM, Sirugo G, Gumbo T. Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients. Epub 2015 Jul 27. PMID: 26248372; PMCID: PMC4576092 Antimicrob Agents Chemother. 2015 Oct;59(10):6337–6343. https://doi.org/10.1128/AAC.01050-15.

[26] Chen Xiao, Guo Xiaojing, Xu Jinfang, Wei Lianhui, Chen Chenxin, Liang Jizhou, Zheng Yi, Ye Xiaofei. Application of machine learning method in detection of adverse reaction signals of brigatinib in FAERS. Pharmacovigilan China:1-15.

[27] Yu Z, Ye X, Liu H, et al. Predicting lapatinib dose regimen using machine learning and deep learning techniques based on a real-world study. PMID: 35719963; PMCID: PMC9203846 Front Oncol. 2022 Jun 3;12, 893966. https://doi.org/10.3389/fonc.2022.893966.

[28] Zhan M, Chen Z, Ding C, et al. Risk prediction for delayed clearance of high-dose methotrexate in pediatric hematological malignancies by machine learning. Epub 2021 Jun 25. PMID: 34170480 Int J Hematol. 2021 Oct;114(4):483–493. https://doi.org/10.1007/s12185-021-03184-w.

RIGHTS & PERMISSIONS

2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).